Covid-19: As lab execs sell shares worth millions, questions arise

Pfizer, Moderna, Novavax: executives at several American laboratories developing COVID-19 vaccines have recently pocketed millions of dollars by selling shares in their companies—raising questions about the propriety of such a move in the midst of a national health crisis.